GSK broadens drug-development partnership with NPS

08/2/2011 | Reuters

GlaxoSmithKline expanded a collaboration with NPS Pharmaceuticals to take over development and marketing of ronacaleret. The drug was designed to treat osteoporosis, but GSK will develop it as stem cell transplant therapy. The agreement also grants NPS development rights to SB-423557 and SB-423562 for autosomal dominant hypocalcemia with hypercalciuria.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Principal Engineer - Service (US/MI/00/0043/SL) - 14000009CP
Abbott
Chicago, IL
Manager, Business Conduct
Gilead
Foster City, CA
Product Patent Attorney
Gilead
Foster City, CA
Employment Counsel
Gilead
Foster City, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC